Kapvay

Hot Flashes, Smoke, clonidine suppression test + 15 more
Treatment
20 Active Studies for Kapvay

What is Kapvay

ClonidineThe Generic name of this drug
Treatment SummaryClonidine is a medication used to treat high blood pressure, severe pain, and Attention Deficit Hyperactivity Disorder (ADHD). It works by activating alpha-2 adrenoceptors in the body. Clonidine was approved by the FDA in 1974 and has been commonly prescribed ever since.
Catapresis the brand name
image of different drug pills on a surface
Kapvay Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Catapres
Clonidine
1974
447

Effectiveness

How Kapvay Affects PatientsClonidine works by activating certain receptors in the body, which can reduce blood pressure, make you sleepy, and decrease electrical activity in the nerves. The amount of clonidine needed for it to be effective varies from person to person, and it is typically taken twice a day. The usual recommended dose is between 0.1mg to 2.4mg daily.
How Kapvay works in the bodyClonidine works by binding to the Alpha-2 adrenoceptor, a G-protein found in the brain. This binding causes a change in the G-protein's structure, allowing it to interact with an effector. This process can cause decreased blood pressure, inhibited pain signals, and increased sleepiness. It can also affect regulators of blood pressure in certain areas of the brain.

When to interrupt dosage

The advised measure of Kapvay is contingent upon the diagnosed condition, including methadone, diabetic diarrhea and Hypertensive disease. The dosage fluctuates as per the administration technique (e.g. Oral or Tablet) provided in the table below.
Condition
Dosage
Administration
Pheochromocytoma
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Tourette Syndrome
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Hypertensive disease
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Disease
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Attention Deficit and Disruptive Behavior Disorders
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Smoke
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
clonidine suppression test
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
clozapine
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
methadone
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Cancer Pain
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
growth hormone stimulation test
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
diabetic diarrhea
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Hot flashes
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Neuralgia, Postherpetic
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Human Growth Hormone Deficiency
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Attention Deficit Hyperactivity Disorder
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Smoking Cessation
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral
Hot Flashes
, 0.1 mg, 0.2 mg, 0.3 mg, 0.5 mg/mL, 0.1 mg/mL, 0.01 mg/hour, 0.02 mg/hour, 0.03 mg/hour, 0.09 mg/mL, 0.17 mg, 0.26 mg, 0.025 mg, 0.15 mg, 25.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal, For suspension, extended release, For suspension, extended release - Oral, Epidural, Injection, solution - Epidural, Kit, Kit - Oral, Suspension, extended release, Suspension, extended release - Oral

Warnings

Kapvay has five contraindications. It should not be consumed when experiencing any of the conditions enumerated in the following table.Kapvay Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
administration above the C4 dermatome
Do Not Combine
Communicable Diseases
Do Not Combine
bleeding diathesis
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Clonidine may interact with Pulse Frequency
There are 20 known major drug interactions with Kapvay.
Common Kapvay Drug Interactions
Drug Name
Risk Level
Description
1,2-Benzodiazepine
Major
The risk or severity of sedation can be increased when Clonidine is combined with 1,2-Benzodiazepine.
2,5-Dimethoxy-4-ethylthioamphetamine
Major
The risk or severity of sedation can be increased when Clonidine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
Major
The risk or severity of sedation can be increased when Clonidine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
Major
The risk or severity of sedation can be increased when Clonidine is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
Major
The risk or severity of sedation can be increased when Clonidine is combined with 5-methoxy-N,N-dimethyltryptamine.
Kapvay Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats is 126mg/kg. For humans, the lowest toxic dose is 70µg/kg in children, 126µg/kg in women, and 69µg/kg in men. Symptoms of overdose include high or low blood pressure, slow heartbeat, shallow breathing, hypothermia, drowsiness, decreased reflexes, weakness, irritability, and pupil constriction. In severe cases, patients may experience cardiac problems, difficulty breathing, coma, or seizures. It is not recommended to induce vomiting, but gastric lavage or activated charcoal may be helpful if the
image of a doctor in a lab doing drug, clinical research

Kapvay Novel Uses: Which Conditions Have a Clinical Trial Featuring Kapvay?

231 active trials are being conducted to investigate the potential of Kapvay in aiding Smoking Cessation, managing Menopause symptoms and alleviating severe Cancer pain.
Condition
Clinical Trials
Trial Phases
Attention Deficit Hyperactivity Disorder
63 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2
Smoking Cessation
104 Actively Recruiting
Early Phase 1, Phase 4, Not Applicable, Phase 3, Phase 2, Phase 1
clonidine suppression test
0 Actively Recruiting
growth hormone stimulation test
0 Actively Recruiting
diabetic diarrhea
0 Actively Recruiting
Tourette Syndrome
0 Actively Recruiting
Neuralgia, Postherpetic
0 Actively Recruiting
Human Growth Hormone Deficiency
4 Actively Recruiting
Phase 2, Phase 4, Phase 3
Hot Flashes
6 Actively Recruiting
Phase 2, Not Applicable, Phase 3
Cancer Pain
0 Actively Recruiting
Disease
6 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
methadone
0 Actively Recruiting
Attention Deficit and Disruptive Behavior Disorders
6 Actively Recruiting
Not Applicable, Phase 1, Phase 2
clozapine
0 Actively Recruiting
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Pheochromocytoma
0 Actively Recruiting
Smoke
0 Actively Recruiting

Kapvay Reviews: What are patients saying about Kapvay?

5Patient Review
11/19/2011
Kapvay for Attention Deficit Disorder with Hyperactivity
This treatment has been great for my daughter. She's four years old and was diagnosed with ADHD, so she takes Kapvay and risperidone twice a day. They both work well and help her stay focused and calm throughout the day. It was hard to get her to take the pills at first, but after a while she was able to do it on her own and even tells me when it is time to take them.
5Patient Review
1/12/2012
Kapvay for "Change of Life" Signs
This drug has been a game-changer for my five-year-old. She's been sleeping through the night since we started using it six months ago.
3.7Patient Review
11/14/2012
Kapvay for Attention Deficit Disorder with Hyperactivity
My son is 12 years old. He is Autistic, ODD, ADHD and Bi-polar. This medication was suppose to treat the impulsive rage that he has. It helped at first, but after the second week, it stopped working. My doctor just decided to change drugs due to how intense my son's 'freak out' moments were getting. The drug did work very well at first-- for a full two days we had NO drama!!! That was a welcomed blessing from above!
3Patient Review
7/17/2012
Kapvay for Attention Deficit Disorder with Hyperactivity
My daughter didn't seem to concentrate or focus any better on this medication, and it was quite expensive to maintain the prescribed dosage. She did have fewer upper respiratory infections, however.
2.3Patient Review
5/28/2013
Kapvay for Attention Deficit Disorder with Hyperactivity
If your child has accidentally taken a double dose of this medication, it's important to seek professional medical advice right away.

Patient Q&A Section about kapvay

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Kapvay prescribed for?

"This drug is used to treat ADHD by itself or with other drugs as part of a comprehensive treatment plan that also includes psychological and social therapies, among other treatments."

Answered by AI

Is Kapvay the same as clonidine?

"Both Kapvay and Catapres contain the drug clonidine. The doses of the two drugs are usually similar. However, Kapvay is used to treat ADHD, while Catapres is used to treat high blood pressure. Catapres is available as an immediate-release tablet, while Kapvay is available as an extended-release tablet."

Answered by AI

How does Kapvay work for ADHD?

"The drug Kapvay works by targeting alpha-2 receptors in the brain in order to potentially reduce symptoms of hyperactivity by altering the way the brain processes emotions, attention, and behavior. While the method by which this drug treats ADHD is not known for certain, the FDA approved its use for pediatric patients aged 6-17 in September of 2010."

Answered by AI

Is Kapvay a stimulant?

"Kapvay is a prescription medicine that is used to treat attention deficit hyperactivity disorder (ADHD). It is supplied as an extended-release tablet. Your doctor may prescribe Kapvay alone or together with other ADHD medicines. Kapvay is not a central nervous system (CNS) stimulant."

Answered by AI

Clinical Trials for Kapvay

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.
Phase 1
Recruiting
St. Jude Children's Research HospitalAndrew Heitzer, PhD
Have you considered Kapvay clinical trials? We made a collection of clinical trials featuring Kapvay, we think they might fit your search criteria.Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of Dr. Vince Clinical Research in Overland Park, United States.

ATI-1013 for Smoking Cessation

23 - 59
All Sexes
Overland Park, KS
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the body, does drug ATI-1013 trigger an immune response, and the effects of drug ATI-1013 on nicotine levels within the body. The clinical trial will compare drug ATI-1013 to a placebo (a look-alike substance that contains no drug) to see if drug ATI-1013 has comparable safety. Participants will have a Screening visit (Day -28 to -3) and will be admitted on Day -2. Each participant will receive one intravenous (IV) infusion of ATI-1013 or placebo (Day 1). Participants will remain in-clinic for at least 48 hours post-dose and return for follow-up visits on Days 7, 21, 42, 56, and 84, with telephone check-ins on Days 5, 14, 28, and 70. Participants will keep a diary of their cigarette use and smoking behaviors.
Phase 1
Recruiting
Dr. Vince Clinical ResearchMatthew Kalnik, PhDAntidote Therapeutics, Inc
Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)
Recruiting
Device
UCSF Nancy Friend Pritzker Psychiatry Building
Have you considered Kapvay clinical trials? We made a collection of clinical trials featuring Kapvay, we think they might fit your search criteria.Go to Trials
Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX
The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.
Waitlist Available
Online Trial
The University of Texas at Austin
Image of Hoskinson Health and Wellness Clinic in Gillette, United States.

Biofeedback and Lifestyle Interventions for ADHD

7 - 18
All Sexes
Gillette, WY
The Pediatric Healing Minds II intervention includes a biofeedback component, breathing practices nutrition and exercise counseling. Biofeedback is a type of mind-body technique used to control body functions such as heart, lung and muscle responses. Biofeedback uses therapeutic techniques that aim to help study participants gain more awareness and control over certain physiological functions in their bodies. It involves the use of electronic monitoring equipment to provide real-time information about physiological processes such as heart rate, HRV, coherence and muscle tension. This information is then provided back to the study participant, allowing them to learn how to consciously regulate these processes. During the sessions parents are expected to attend and participate. Study participants and parents will have access to a video that provides instructions for placement of the Heart Math single small ear lobe or finger sensor. Breathing Practices include alternate nostril, qi gong and other breathing practices. Nutrition counseling includes nutrition supplementation to correct deficiencies, dietary education and an age-and gender-specific diet prescription based on the Mediterranean Diet. Exercise counseling includes developmentally appropriate guidelines for cardiopulmonary, strength and flexibility activities based on guidelines from the American College of Sports Medicine (ACSM) and the American Academy of Pediatrics (AAP). The objective of this research proposal is to examine the combined effects of an integrative approach including biofeedback, breathing practices, nutrition and exercise counseling intervention (Healing Minds II), on symptoms and severity of ADHD, impulsivity and attention (e.g., QB continuous performance test) in youth 7-18 years of age. The investigators hypothesize that ADHD symptoms and severity, impulsivity and attention will be significantly improved and coherence increased after participation in the 6-month intervention. The investigators also propose that ADHD severity in those patients with prescribed medication but poorly-controlled ADHD will demonstrate the greatest improvement compared to those not prescribed medication and those who have well-controlled ADHD.
Waitlist Available
Has No Placebo
Hoskinson Health and Wellness ClinicInara McMaster, MDHoskinson Health and Wellness Clinic
Image of Mayo Clinic in Rochester, United States.

Smoking Cessation Medications for Pancreatitis

18+
All Sexes
Rochester, MN
The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoking, at its standard dose. For those who are unable to stop smoking after 6 weeks of treatment, they will be randomly selected to either 1) increase their dose of varenicline, 2) combine varenicline with bupropion (another medication that helps with smoking cessation) or continue on the standard dose of varenicline. At the end of 12 weeks of treatment, participants will be asked if they have stopped smoking with confirmation done by measuring carbon monoxide levels in their breath.
Phase 2
Recruiting
Mayo ClinicSamuel Han, MD
Have you considered Kapvay clinical trials? We made a collection of clinical trials featuring Kapvay, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security